Janssen hopes European Xeplion launch will elbow Zyprexa aside
This article was originally published in Scrip
The European Commission has given marketing authorisation to Janssen-Cilag's once-a-month injectable antipsychotic Xeplion (paliperidone palmitate) for the treatment of schizophrenia, but the drug is unlikely to be marketed anywhere in Europe much before the autumn of this year. A company spokesperson told Scrip that it would be at least a year or even 18 months before the product is rolled out across the European Union. The company was unable to comment in detail on a timetable for either reimbursement discussion or outline a marketing strategy.